<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://test.ccga.io/index.php?action=history&amp;feed=atom&amp;title=HAEM4%3AMyelodysplastic%2FMyeloproliferative_Neoplasms_%28MDS%2FMPN%29</id>
	<title>HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://test.ccga.io/index.php?action=history&amp;feed=atom&amp;title=HAEM4%3AMyelodysplastic%2FMyeloproliferative_Neoplasms_%28MDS%2FMPN%29"/>
	<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Myelodysplastic/Myeloproliferative_Neoplasms_(MDS/MPN)&amp;action=history"/>
	<updated>2026-04-30T21:12:36Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.5</generator>
	<entry>
		<id>https://test.ccga.io/index.php?title=HAEM4:Myelodysplastic/Myeloproliferative_Neoplasms_(MDS/MPN)&amp;diff=13207&amp;oldid=prev</id>
		<title>Bailey.Glen at 21:23, 4 December 2023</title>
		<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Myelodysplastic/Myeloproliferative_Neoplasms_(MDS/MPN)&amp;diff=13207&amp;oldid=prev"/>
		<updated>2023-12-04T21:23:07Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 16:23, 4 December 2023&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l13&quot;&gt;Line 13:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 13:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==General Disease Overview / Description of Cancer Category==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==General Disease Overview / Description of Cancer Category==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The MDS/MPNs include a category of myeloid malignancies with overlapping characteristics of myelodysplastic syndrome ([[Myelodysplastic Syndromes (MDS)|MDS]]) and myeloproliferative neoplasm ([[Myeloproliferative Neoplasms (MPN)|MPN]]) at the time of initial presentation (disease onset).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The MDS/MPNs include a category of myeloid malignancies with overlapping characteristics of myelodysplastic syndrome ([[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM4:&lt;/ins&gt;Myelodysplastic Syndromes (MDS)|MDS]]) and myeloproliferative neoplasm ([[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM4:&lt;/ins&gt;Myeloproliferative Neoplasms (MPN)|MPN]]) at the time of initial presentation (disease onset).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==WHO Classification Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==WHO Classification Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Chronic &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myelomonocytic Leukemia (CMML)&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Chronic &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myelomonocytic leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Juvenile &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myelomonocytic Leukemia (JMML)&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Juvenile &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myelomonocytic leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Myelodysplastic/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myeloproliferative Neoplasms &lt;/del&gt;with &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Ring Sideroblasts &lt;/del&gt;and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Thrombocytosis (MDS/MPN-RS-T)&lt;/del&gt;|MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Myelodysplastic/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myeloproliferative neoplasm &lt;/ins&gt;with &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SF3B1 mutation &lt;/ins&gt;and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;thrombocytosis&lt;/ins&gt;|MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[Myelodysplastic/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myeloproliferative Neoplasms (MDS/MPN)&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Unclassifiable&lt;/del&gt;|MDS/MPN, Unclassifiable]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Myelodysplastic/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myeloproliferative neoplasm&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;NOS&lt;/ins&gt;|MDS/MPN, Unclassifiable]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Other Related Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Other Related Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l40&quot;&gt;Line 40:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 40:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#Previously diagnosed MPN developed cytopenia(s): classification must be based on initial presentation; avoid “reclassification”.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#Previously diagnosed MPN developed cytopenia(s): classification must be based on initial presentation; avoid “reclassification”.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#Cases with well-defined fusions that can be classified otherwise: &#039;&#039;[[Chronic &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myeloid Leukemia (CML), BCR-ABL1 Positive&lt;/del&gt;|BCR-ABL1]]&#039;&#039;; fusion involving &#039;&#039;[[Myeloid/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lymphoid Neoplasms &lt;/del&gt;with PDGFRA &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Rearrangement&lt;/del&gt;|PDGFRA]], [[Myeloid/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lymphoid Neoplasms &lt;/del&gt;with PDGFRB &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Rearrangement&lt;/del&gt;|PDGFRB]]&#039;&#039;, or &#039;&#039;[[Myeloid/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lymphoid Neoplasms &lt;/del&gt;with FGFR1 &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Rearrangement&lt;/del&gt;|FGFR1]]&#039;&#039;; or &#039;&#039;[[Myeloid/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lymphoid Neoplasms &lt;/del&gt;with &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;PCM1-&lt;/del&gt;JAK2|PCM1-JAK2]]&#039;&#039;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#Cases with well-defined fusions that can be classified otherwise: &#039;&#039;[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Chronic &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myeloid leukaemia&lt;/ins&gt;|BCR-ABL1]]&#039;&#039;; fusion involving &#039;&#039;[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Myeloid/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lymphoid neoplasm &lt;/ins&gt;with PDGFRA &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rearrangement&lt;/ins&gt;|PDGFRA]], [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Myeloid/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lymphoid neoplasm &lt;/ins&gt;with PDGFRB &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rearrangement&lt;/ins&gt;|PDGFRB]]&#039;&#039;, or &#039;&#039;[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Myeloid/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lymphoid neoplasm &lt;/ins&gt;with FGFR1 &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rearrangement&lt;/ins&gt;|FGFR1]]&#039;&#039;; or &#039;&#039;[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Myeloid/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lymphoid neoplasm &lt;/ins&gt;with JAK2 &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rearrangement&lt;/ins&gt;|PCM1-JAK2]]&#039;&#039;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key wikidatabase:diff:1.41:old-12374:rev-13207:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Bailey.Glen</name></author>
	</entry>
	<entry>
		<id>https://test.ccga.io/index.php?title=HAEM4:Myelodysplastic/Myeloproliferative_Neoplasms_(MDS/MPN)&amp;diff=12374&amp;oldid=prev</id>
		<title>Bailey.Glen: Created page with &quot;==Primary Author(s)*==  Linsheng Zhang, MD, PhD  __TOC__  ==Graphical Data Links==  &#039;&#039;&#039;MDS, MDS/MPN and MPN Tables&#039;&#039;&#039; - A comprehensive list of copy number alterations and CN-...&quot;</title>
		<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Myelodysplastic/Myeloproliferative_Neoplasms_(MDS/MPN)&amp;diff=12374&amp;oldid=prev"/>
		<updated>2023-11-03T18:01:13Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Primary Author(s)*==  Linsheng Zhang, MD, PhD  __TOC__  ==Graphical Data Links==  &amp;#039;&amp;#039;&amp;#039;MDS, MDS/MPN and MPN Tables&amp;#039;&amp;#039;&amp;#039; - A comprehensive list of copy number alterations and CN-...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Primary Author(s)*==&lt;br /&gt;
&lt;br /&gt;
Linsheng Zhang, MD, PhD&lt;br /&gt;
&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
==Graphical Data Links==&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;MDS, MDS/MPN and MPN Tables&amp;#039;&amp;#039;&amp;#039; - A comprehensive list of copy number alterations and CN-LOH detectable by CMA testing with strong diagnostic, prognostic and treatment implications in MDS, MDS/MPN and MPN. Tables derived from Kanagal-Shawanna et al., 2018 [PMID [https://www.ncbi.nlm.nih.gov/pubmed/?term=30377088 30377088]] with permission from Cancer Genetics. &amp;#039;&amp;#039;See [[MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray]].&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
No specific recurrent genetic abnormalities are identified for this category of myeloid neoplasms.&lt;br /&gt;
&lt;br /&gt;
==General Disease Overview / Description of Cancer Category==&lt;br /&gt;
&lt;br /&gt;
The MDS/MPNs include a category of myeloid malignancies with overlapping characteristics of myelodysplastic syndrome ([[Myelodysplastic Syndromes (MDS)|MDS]]) and myeloproliferative neoplasm ([[Myeloproliferative Neoplasms (MPN)|MPN]]) at the time of initial presentation (disease onset).&lt;br /&gt;
&lt;br /&gt;
==WHO Classification Pages (Includes Links to Content)==&lt;br /&gt;
&lt;br /&gt;
*[[Chronic Myelomonocytic Leukemia (CMML)]]&lt;br /&gt;
*[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]]&lt;br /&gt;
*[[Juvenile Myelomonocytic Leukemia (JMML)]]&lt;br /&gt;
*[[Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)|MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)]]&lt;br /&gt;
*[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]]&lt;br /&gt;
&lt;br /&gt;
==Other Related Pages (Includes Links to Content)==&lt;br /&gt;
&lt;br /&gt;
Put your text here (use &amp;quot;Link&amp;quot; icon at top of page)&lt;br /&gt;
&lt;br /&gt;
==Additional Information&amp;lt;ref&amp;gt;Arber DA, et al., (2017). Introduction and overview of the classification of myeloid neoplasms, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p23.&amp;lt;/ref&amp;gt;==&lt;br /&gt;
&lt;br /&gt;
Features of MDS : normal or low blood cell counts; dysplastic changes&lt;br /&gt;
&lt;br /&gt;
Features MPN : Elevated blood cell counts in at least one lineage; hypercellular bone marrow; hepatosplenomegaly&lt;br /&gt;
&lt;br /&gt;
The blasts are &amp;lt; 20% in the blood (leukocytes) and bone marrow (nucleated cells).&lt;br /&gt;
&lt;br /&gt;
Mutations in genes encoding encode components of RAS dependent pathways, and epigenetic regulators such as &amp;#039;&amp;#039;TET2&amp;#039;&amp;#039; and &amp;#039;&amp;#039;ASXL1&amp;#039;&amp;#039;, are common, supporting clonal processes; however, diagnostic or specific mutations for this entity of myeloid neoplasms are not identified.&lt;br /&gt;
&lt;br /&gt;
The following situations may have the same or similar clinical and laboratory presentations with MDS/MPN, however, they are exclude from this category:&lt;br /&gt;
&lt;br /&gt;
#Previously diagnosed MPN developed cytopenia(s): classification must be based on initial presentation; avoid “reclassification”.&lt;br /&gt;
#Cases with well-defined fusions that can be classified otherwise: &amp;#039;&amp;#039;[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive|BCR-ABL1]]&amp;#039;&amp;#039;; fusion involving &amp;#039;&amp;#039;[[Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|PDGFRA]], [[Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|PDGFRB]]&amp;#039;&amp;#039;, or &amp;#039;&amp;#039;[[Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement|FGFR1]]&amp;#039;&amp;#039;; or &amp;#039;&amp;#039;[[Myeloid/Lymphoid Neoplasms with PCM1-JAK2|PCM1-JAK2]]&amp;#039;&amp;#039;.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Notes==&lt;br /&gt;
&amp;lt;nowiki&amp;gt;*&amp;lt;/nowiki&amp;gt;Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;*&amp;lt;/nowiki&amp;gt;The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.&lt;/div&gt;</summary>
		<author><name>Bailey.Glen</name></author>
	</entry>
</feed>